Dysfibrinogenemia
The dysfibrinogenemias are a group of autosomal dominant disorders of qualitatively abnormal fibrinogens.[1] There are more than 350 different fibrinogen abnormalities, each named after the place where it was discovered.[2] Each dysfibrinogenemia is associated with slightly different effects on the thrombin time and on normal clotting. Some dysfibrinogenemias cause abnormal bleeding or even thrombosis, while others have no effect on either bleeding or thrombosis.[3]
Examples
 |
- Amsterdam is a major defect, characterized by aggregation of fibrin monomers, prolonged thrombin time, and an inhibitory effect on normal clotting - but it is asymptomatic.
- Detroit is a major defect, there is fibrinopeptide release, the thrombin time is prolonged, there is an inhibitory effect on normal clotting and there is abnormal bleeding.
- Wiesbaden is a major defect, there is aggregation of fibrin monomers, the thrombin time is prolonged, there is an inhibitory effect on normal clotting and there is both bleeding and thrombosis.
References
- ^ Dysfibrinogenemia at eMedicine
- ^ McDonagh, J (2001). "Dysfibrinogenemia and other disorders of fibrinogen structure or function". In Colman R, Hirsh J, Marder V, Clowes A, George J (eds.). Hemostasis and Thrombosis (4th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 855–92. ISBN 978-0-7817-1455-6.
- ^ Hayes, T (2002). "Dysfibrinogenemia and thrombosis". Archives of Pathology & Laboratory Medicine. 126 (11): 1387–90. doi:10.1043/0003-9985(2002)126<1387:DAT>2.0.CO;2 (inactive 2016-10-16). PMID 12421146.
{{cite journal}}: CS1 maint: DOI inactive as of October 2016 (link)
 | This article about a disease of the blood or immune system is a stub. You can help Wikipedia by expanding it. |